

Guide to completing the COSENTYX® (secukinumab) Intravenous (IV) Formulation Start Form



Phone:

844-COSENTYX (844-267-3689)



гах

844-666-1366 or 800-343-9117



Online:

www.cosentyxhcp.com



Portal:

www.covermymeds.health

For questions or support, reach out to your dedicated Novartis Access and Reimbursement Manager (ARM) or contact Novartis Patient Support.



Novartis Patient Support

Getting patients started

Novartis Patient Support will work with your practice to help your patient start on COSENTYX® (secukinumab). Begin the process by completing the Start Form. We have outlined the key information below to help ensure a smoother process for your office and your patient.


All REQUIRED fields must be filled out for the Start Form to be processed as complete. An incomplete Start Form may delay the start of treatment.

| Please note that providers, | Page 1 | | |
|--|--|--|--|
| along with their patients, can complete the Start Form online at the CoverMyMeds® portal or | Sign up online at www.covermymeds.health . Or complete entire form and fax to Novartis Patient Support at 844-666-1366 or 800-343-9117. Questions? Contact 844-267-3689. An incomplete Start Form may delay the start of treatment. | | |
| by faxing the completed Start Form to the number listed. | Novartis Patient Support™ IV Formulation of COSENTYX® (secukinumab) START FORM Patient Support™ | | |
| This Start Form is specifically for the IV formulation of COSENTYX. There is a separate Start Form for the subcutaneous formulation. | 1. Please check the box that indicates the support your patient needs from Novartis Patient Support. Intravenous (IV) use—includes (select one): Benefits verification Only: Benefits verification without prior authorization or appeals support Benefit verification Monthly - optional (select if applicable): Benefit verifications conducted monthly based on the patient's treatment date 2. Patient Information Service Support: Support including the initial benefits verification through prior authorization, appeals and assessment of program eligibility Benefit Verification Monthly - optional (select if applicable): Benefit Verification Sonducted monthly based on the patient's treatment date **Phone Number—Well like pyou informed through non-marketing calls and texts! | | |
| Look for this symbol as you fill out the Start Form. It indicates a required field. | Sex for Clinical Use: Male Female OK to Leave Voicemail for COSENTYX. Yes No Preferred Language: English Spanish Other: Address (No POBox) City State ZIP Email | | |
| Indicate the type of support necessary for your patient here. | It give permission to disclose my personal health information to the following Caregiver (optional): ——————————————————————————————————— | | |
| Get patient and/or authorized representative consent. | X | | |
| Patients can check this box to sign up for the Co-Pay Plus offer. | 4. Insurance Information Please Include a copy (front and back) of the patient's insurance card(s) and/or complete the section below. Check all that apply: Patient is the Policy Holder Patient is Uninsured Image(s) of Insurance Card(s) Included Primary Medical Insurance Private Medicare Advantage Medicare A/B Medicaid Other: | | |
| Don't forget your patient's insurance information. We | Insurance/Payer Plan Name Policy Phone Number Member ID Number Group Number | | |
| need to verify all their benefits. | Secondary Medical Insurance | | |
| Please do not fax patient medical records as any that | Member ID Number Group Number DO NOT FAX PATIENT MEDICAL RECORDS. ANY MEDICAL RECORDS SHARED WILL BE DESTROYED. | | |
| are shared will be destroyed. | To report an adverse event, call 1-888-NOW-NOVA or visit www.novartis.com/report FA-11410834 FA-11410834 Page 1 of 3 (seculariumab) | | |



Getting patients started (cont)

All REQUIRED fields must be filled out for the Start Form to be processed as complete. An incomplete Start Form may delay the start of treatment.





Novartis Patient Support

Your patients are our top priority

Novartis Patient Support is a comprehensive program that is designed to help your eligible patients start, stay, and save on COSENTYX® (secukinumab).

We support you and your patient's journey with:

- Dedicated assistance with access and reimbursement
- Personalized support for your patients on therapy
- Single points of contact for you and your patients



Our offerings include:



Insurance Support

Help navigating the insurance process, including benefits verification and support with the prior authorization and appeals processes.



Financial Support

Assistance with relevant savings options for your eligible patients, including \$0 Co-Pay Plus* offer and affordability programs.



Acquisition, Coding, and Billing Support

Guidance on appropriate distributors, codes, and billing.



Ongoing Support

Dedicated assistance from our team and educational resources to help your patients get started on treatment and guide them along the way.



Questions?

For more information, call Novartis Patient Support at 844-COSENTYX (844-267-3689), Monday-Friday, 8:00 AM-8:00 PM ET, excluding holidays, or visit www.cosentyxhcp.com

*Limitations apply. Subject to annual co-pay benefit limit. Offer not valid under Medicare, Medicaid, or any other federal or state programs. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional limitations may apply. See complete Terms & Conditions at www.support.cosentyx.com for details.

The information herein is provided for educational purposes only. Novartis cannot guarantee health plan or reimbursement. Coverage and reimbursement may vary significantly by health plan, patient, and setting of care. It is the sole responsibility of the health care provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.





9/25



Sign up online at <u>www.covermymeds.health</u>. Or complete entire form and fax to Novartis Patient Support at 844-666-1366 or 800-343-9117. Questions? Contact 844-267-3689. An incomplete Start Form may delay the start of treatment.

Novartis Patient Support™

IV Formulation of COSENTYX® (secukinumab) START FORM

* = REQUIRED

| 1. Please check the box that indicates the support your patient need | ls from Novartis Patient Support. | | | | |
|--|--|--|--|--|--|
| Intravenous (IV) use—includes (select one): | | | | | |
| ☐ Benefits Verification Only: Benefits verification without prior authorization or appeals support | Full Service Support: Support including the initial benefits verification through prior authorization, appeals and assessment of program eligibility Benefit Verification Monthly - optional (select if applicable): Benefit verifications conducted monthly based on the patient's | | | | |
| ☐ Benefit Verification Monthly - optional (select if applicable): Benefit verifications conducted monthly based on the patient's treatment date | | | | | |
| 2. Patient Information | treatment date | | | | |
| | ☐ Mobile ☐ Home | | | | |
| ★ First Name ★ Last Name | Phone Number—We'll keep you informed through non-marketing calls and texts.† | | | | |
| ➤ Sex for Clinical Use: Male Female Date of Birth (MM/DD/YYYY) | e OK to Leave Voicemail for COSENTYX: Yes No | | | | |
| ★ Address (No PO Box) | Preferred Language: English Spanish Other: | | | | |
| ★ City ★ State ★ ZIP | - Email | | | | |
| I give permission to disclose my personal health information to the following Care | egiver (optional): | | | | |
| 3 1 pr | | | | | |
| Caregiver Name Relationship to Patient Car | Mobile ☐ Home egiver Phone Number—We'll keep you informed through non-marketing calls and texts! | | | | |
| 3. Patient Authorization and Additional Enrollment Consents X | I have read and agree to the Patient Authorization on page 3. Check here if signed by an | | | | |
| ▶ Patient/Authorized Representative Signature | Date (MM/DD/YYYY) Authorized Representative. | | | | |
| CO-PAY PLUS [‡] FOR COSENTYX. Pay as little as \$0 | | | | | |
| I have read and agree to the Co-Pay Plus Terms and Conditions on page 3. | | | | | |
| 4. Insurance Information Please include a copy (front and back) of the page 1 | atient's insurance card(s) and/or complete the section below. | | | | |
| Check all that apply: Patient Is the Policy Holder Patient Is Uninsured | | | | | |
| ➤ Primary Medical Insurance Private | Medicare A/B Medicaid Other: | | | | |
| Insurance/Payer Plan Name | Policy Phone Number | | | | |
| Member ID Number Group Number | Group Number | | | | |
| Secondary Medical Insurance Private Medicare Advantage | Medicare A/B Medicaid Other: | | | | |
| Insurance/Payer Plan Name | Policy Phone Number | | | | |
| Member ID Number Group Number | | | | | |

DO NOT FAX PATIENT MEDICAL RECORDS. ANY MEDICAL RECORDS SHARED WILL BE DESTROYED.

To report an adverse event, call 1-888-NOW-NOVA or visit www.novartis.com/report





Sign up online at <u>www.covermymeds.health</u>. Or complete entire form and fax to Novartis Patient Support at 844-666-1366 or 800-343-9117. Questions? Contact 844-267-3689. An incomplete Start Form may delay the start of treatment.

Novartis Patient Support

IV Formulation of COSENTYX® (secukinumab) START FORM

* = REQUIRED

| | | | _ | | |
|---|---|---|--|---|--|
| Patient Name | | | Date of Birth (MM/DD/YY) | ★ Date of Birth (MM/DD/YYYY) | |
| 5. Prescriber Informat | ion | | | | |
| *> First Name | * Last Name | | Provider Transaction Access Number (PTAN) | | |
| * Address | | | ★ Practice Name | | |
| * City | * State | * ZIP | ★ Practice Phone Number | | |
| ★ Prescriber NPI Number | | | Practice Contact Name | | |
| * Tax ID Number | | | Practice Contact Phone Number | r Practice Fax | |
| 6. Site of Administration please complete the inform | | nd to send your pat | ient to another site to receive COSENT | YX® (secukinumab) IV formulation, | |
| Location: Outpatie | nt Facility Physician's | Office Home Ir | nfusion Other | | |
| If alternate site of service | is known, please fill out t | the details below: | | | |
| | | | | / / | |
| ★ Site Name | | Expected COSENTYX Treatment Date (MM/DD/YYYY) | | | |
| * Address | | | Site NPI Number | Site Tax ID Number | |
| * City * State | | * ZIP | ★ Site Contact Name | | |
| | | | Site Phone Number | | |
| | | | Office Fax | | |
| 7. Additional Information | on | | | | |
| Primary Diagnosis/IC | CD-10-CM Codes (check o | ne): | | | |
| L40.5 Psoriatic Arthritis | M45.0 Ankylosing Sp | oondylitis M45 | 5.A Non-Radiographic Axial Spondyloa | rthritis | |
| Other ICD-10-CM Code | e(s): | _ | | | |
| Secondary Diagnosis/Sp | | tions (optional): | | | |
| Prescriber Attestation | n | | | | |
| I certify the above therapy is COSENTYX to the patient n ("Novartis"), or the Novartis F offered for sale, trade, or bar and not for remuneration of a that no medical records wi patient, who has authorize Support. To complete this | medically necessary and this amed on this form. I certify tha Patient Assistance Foundation ter, returned for credit, or subnany sort. I understand that Novill be sent to Novartis Patient | t any medication rece , Inc., and its service p nitted for reimbursem rartis and NPAF may r : Support along with • law to disclose the | te to the best of my knowledge. I certify I am eived from Novartis Pharmaceuticals Corpor providers ("NPAF"), will be used only for the parent in any form. I acknowledge that NPAF is evise, change, or terminate their respective this Start Form. I have discussed the Nov ir information to Novartis for the limited parphone, text, and email. | ration, its affiliates and service providers patient named on this form and will not be exclusively for purposes of patient care programs at any time. I acknowledge vartis Patient Support Program with my | |
| X Prescriber Signature | X Prescriber Signature ★ Prescriber Name (Print Name) ★ Date (MM/DD/Y) | | | | |

DO NOT FAX PATIENT MEDICAL RECORDS. ANY MEDICAL RECORDS SHARED WILL BE DESTROYED.



Novartis Patient Support

Patient Authorization. I authorize my healthcare providers, pharmacies and health insurers, and their service providers ("Providers") to disclose information relating to my insurance benefits, medical condition, treatment, and prescription details ("Personal Information") to Novartis Pharmaceuticals Corporation, its affiliates and service providers ("Novartis") and the Novartis Patient Assistance Foundation, Inc., and its service providers ("NPAF") so they can provide the following support services (the "Services"):

- Help coordinate insurance coverage for, access to, and receipt of my medication.
- Communicate with me about possible financial assistance, including Novartis copay or NPAF programs, and, if I am enrolled, administer my participation in those programs.
- Communicate with me about my medication and treatment, including reminders, health and lifestyle tips, and product and other related information. Communications may be customized based on Personal Information obtained from my Providers.
- Conduct quality assurance and other internal business activities and ask for feedback related to the Services or my treatment.

In delivering the Services, Novartis and NPAF may share my Personal Information with each other, with my Providers, or with government agencies or other financial assistance programs that might help me pay for my medication. They may combine information collected from me with information collected from other sources and use that information to administer the Services. My pharmacies or other healthcare providers may receive payment from Novartis or NPAF for providing certain Services, such as medication or refill reminders, based on my enrollment or participation. Once I authorize disclosure of my Personal Information, it may no longer be protected by federal health privacy law and applicable state laws. I understand I do not have to sign this Authorization to get my medication or insurance coverage, that I have a right to a copy, and can cancel this Authorization at any time by calling 844-267-3689 or by writing to:

Novartis Patient Support
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080

This Authorization will expire 5 years after I sign it, or earlier if required by state law, unless I cancel it sooner. For Maryland healthcare providers, this authorization expires 1 year from the date of signature. If I cancel it, I may no longer qualify for Services from Novartis or NPAF, but it will not impact my Provider's treatment or my insurance benefits. I also understand that if a Provider is disclosing my Personal Information to Novartis or NPAF on an authorized, ongoing basis, my cancellation will be effective with respect to that Provider as soon as they receive notice of my cancellation. Cancellation will not affect prior uses or disclosures.

Please see full Novartis Pharmaceuticals Corporation Privacy Policy and the Mobile Terms of Use.

*Novartis Patient Support may call and text you at the numbers provided for non-marketing purposes (eg, to help you access and start on COSENTYX). Calls may be autodialed or prerecorded. Message and data rates may apply. You may change your communication preferences at any time by calling 844-267-3689.

*Co-Pay Plus Terms & Conditions. Offer valid only when used with commercial health insurance.

Offer is not available where:

- the patient has federal or state health plan benefits (eg, Medicare, Medicaid, TRICARE, VA);
- the health plan reimburses for the entire cost of the drug;
- · the health plan provides no coverage for the drug; or
- · prohibited by law.

The amount of funding available from the Program is subject to an annual limit. Novartis reserves the right to discontinue the availability of co-pay assistance if, at any time, Novartis determines that the patient is subject to a co-pay maximizer program. Co-pay maximizers are programs implemented by health plans in which the amount of the patient's out-of-pocket cost is increased to reflect the availability of support offered by a manufacturer assistance program. The patient is responsible for all costs once available funding from the Program is exhausted.

The Program is designed exclusively for the benefit of the patient. The amount of available funding may be reduced or eliminated if it is not credited by the patient's health plan toward the patient's out-of-pocket obligations (eg, deductibles, annual out-of-pocket maximums). Program funding may also be reduced or eliminated if the patient's health plan, directly or indirectly, adjusts, reduces, or waives the patient's health plan benefits based on the availability of, or the patient's enrollment in, the Program, or otherwise acts in a manner that materially affects these Terms and Conditions.

Only the patient or their legal guardian or caregiver may enroll the patient in the Program. Health plans, specialty pharmacies, pharmacy benefit managers, and their agents and representatives (individually and collectively "Plan Administrators"), are prohibited from enrolling patients in the Program.

Patients in the Program are responsible for notifying Novartis of any change in their prescription drug health plan coverage that may conflict or otherwise affect compliance with these Terms and Conditions. By accepting Program funding from Novartis on behalf of participating patients, Plan Administrators agree to not take any action that materially affects compliance with these Terms and Conditions.

Patients may not seek reimbursement for the value received from the Program from any other party (eg, health plans, flexible spending or healthcare savings accounts). Patients are responsible for complying with any applicable limitations and requirements of their health plan related to their use of the Program.

Valid only in the United States and Puerto Rico. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts.

The Program is not health insurance, and may not be combined with any third-party rebate, coupon, or offer. Novartis reserves the right to rescind, revoke, or amend the Program at any time without notice.



